Skip to main
PMN
PMN logo

PMN Stock Forecast & Price Target

PMN Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProMIS Neurosciences Inc. demonstrates a promising outlook due to favorable biomarker and safety data surrounding its lead candidate, PMN310, which supports its mechanistic advantage and potential for clinical advancement. The company's innovative platform has successfully identified novel therapeutic targets, exemplified by PMN267's dual selectivity profile, which may enhance efficacy and safety across a range of neurodegenerative diseases. Additionally, the absence of adverse events such as ARIA in PMN310 strengthens confidence in its safety profile compared to existing treatments, providing multiple opportunities for successful clinical outcomes and financial upside.

Bears say

ProMIS Neurosciences's financial outlook appears negative due to a reported net loss of $11.6 million, translating to a loss of $0.24 per share in the third quarter of 2025, indicating ongoing financial struggles. Additionally, challenges related to potential partnership risks, an anticipated slow market uptake attributed to heightened competition, and risks of near-term dilution further compound the company's fiscal uncertainties. The company's historical inability to achieve profitability, combined with evidence of previously failed therapies in targeting toxic Aβ oligomers, raises concerns about the viability of its core therapeutic approaches in a competitive biotechnology landscape.

PMN has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProMIS Neurosciences Inc (PMN) Forecast

Analysts have given PMN a Strong Buy based on their latest research and market trends.

According to 3 analysts, PMN has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProMIS Neurosciences Inc (PMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.